Last reviewed 2026-04-19 · How we verify

famotidine combinations

Canadian Network for Observational Drug Effect Studies, CNODES · Phase 2 active Small molecule

famotidine combinations is a Small molecule drug developed by Canadian Network for Observational Drug Effect Studies, CNODES. It is currently in Phase 2 development. Also known as: histamine-2 receptor antagonist.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	famotidine combinations
Also known as	histamine-2 receptor antagonist
Sponsor	Canadian Network for Observational Drug Effect Studies, CNODES
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

famotidine combinations CI brief — competitive landscape report
famotidine combinations updates RSS · CI watch RSS
Canadian Network for Observational Drug Effect Studies, CNODES portfolio CI

Frequently asked questions about famotidine combinations

What is famotidine combinations?

famotidine combinations is a Small molecule drug developed by Canadian Network for Observational Drug Effect Studies, CNODES.

Who makes famotidine combinations?

famotidine combinations is developed by Canadian Network for Observational Drug Effect Studies, CNODES (see full Canadian Network for Observational Drug Effect Studies, CNODES pipeline at /company/canadian-network-for-observational-drug-effect-studies-cnodes).

Is famotidine combinations also known as anything else?

famotidine combinations is also known as histamine-2 receptor antagonist.

What development phase is famotidine combinations in?

famotidine combinations is in Phase 2.

Manufacturer: Canadian Network for Observational Drug Effect Studies, CNODES — full pipeline
Also known as: histamine-2 receptor antagonist

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing